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Abstract
Background: Influenza infections may result in different clinical presentations. This study aims to determine the
clinical differences between circulating influenza strains in a young healthy adult population in the tropics.
Methods: A febrile respiratory illness (FRI) (fever ≥ 37.5°C with cough and/or sore throat) surveillance program was
started in 4 large military camps in Singapore on May 2009. Personnel with FRI who visited the camp clinics from
11 May 2009 to 25 June 2010 were recruited. Nasal washes and interviewer-administered questionnaires on
demographic information and clinical features were obtained from consenting participants. All personnel who
tested positive for influenza were included in the study. Overall symptom load was quantified by counting the
symptoms or signs, and differences between strains evaluated using linear models.
Results: There were 434 (52.9%) pandemic H1N1-2009, 58 (7.1%) seasonal H3N2, 269 (32.8%) influenza B, and 10
(1.2%) seasonal H1N1 cases. Few seasonal influenza A (H1N1) infections were detected and were therefore
excluded from analyses, together with undetermined influenza subtypes (44 (1.5%)), or more than 1 co-infecting
subtype (6 (0.2%)). Pandemic H1N1-2009 cases had significantly fewer symptoms or signs (mean 7.2, 95%CI 6.9-7.4,
difference 1.6, 95%CI 1.2-2.0, p < 0.001) than the other two subtypes (mean 8.7, 95%CI 8.5-9.0). There were no
statistical differences between H3N2 and influenza B (p = 0.58). Those with nasal congestion, rash, eye symptoms,
injected pharynx or fever were more likely to have H3N2; and those with sore throat, fever, injected pharynx or
rhinorrhoea were more likely to have influenza B than H1N1-2009.
Conclusions: Influenza cases have different clinical presentations in the young adult population. Pandemic H1N1
influenza cases had fewer and milder clinical symptoms than seasonal influenza. As we only included febrile cases
and had no information on the proportion of afebrile infections, further research is needed to confirm whether the
relatively milder presentation of pandemic versus seasonal influenza infections applies to all infections or only
febrile illnesses.
Background
Influenza infections arising from different influenza
strains may result in different clinical presentations.
Determining these different clinical presentations is use-
ful for epidemiological comparison. Furthermore, having
knowledge of such clinical symptoms may aid clinicians
in determining shifts in influenza strains and managing
selected patients at higher risk of developing complica-
tions from influenza, especially in settings with poor
laboratory resources. Few studies have differentiated the
clinical presentation of different influenza strains, parti-
cularly in the tropics where the spread of influenza differs
from temperate regions [1]. One recent tropical study
explored the differences in presentation among various
influenza subtypes, but was based on limited number of
hospital attendances during the onset of the 2009-H1N1
pandemic [2].
Despite earlier hypotheses that the H1N1-2009 pan-
demic strain would become the predominant influenza
strain in circulation [3], the influenza A (H3N2) and
influenza B subtypes that were in circulation before the
pandemic continue to circulate globally. This provides
the opportunity to compare their clinical features. As
older children and young adults were substantially
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provided the original work is properly cited.affected by the H1N1-2009 outbreaks [4], this study uses
a military respiratory disease surveillance program in tro-
pical Singapore to determine the clinical differences
between circulating influenza strains among young
healthy adults presenting with febrile respiratory illness
[5].
Methods
This study was carried out as part of a respiratory disease
surveillance program within the Singapore military. The
febrile respiratory illness (FRI) (fever ≥ 37.5°C with cough
and/or sore throat) surveillance program was started in 4
large military camps in May 2009 before community
spread of pandemic H1N1-2009 in Singapore [6]. All per-
sonnel with FRI who visited the camps’ primary healthcare
clinics from 11 May 2009 to 25 June 2010 were recruited
into the study - this study therefore excludes milder cases,
and compares the different clinical symptoms among FRI
cases with influenza. Nasal washes from each side of the
nose were taken from consenting participants by trained
medical staff, placed in viral transport media, and sent to
the laboratory for aetiological testing within 24 h. In addi-
tion, interviewer-administered questionnaires on demo-
graphic information and clinical features of infection were
obtained during the clinical consultation, and again at 2
weeks post-consult via telephone interview to identify
symptoms present during the entire illness course.
Written informed consent was obtained. Approval was
given by the military’s Joint Medical Committee for
Research, and the respective institutional review boards of
the National University of Singapore and Australian
National University.
Laboratory methods
To determine aetiology of the FRI cases, we used the
Resplex II (version 2.0, Qiagen, Inc., Valencia, CA, USA)
multiplex PCR assay as previously described in other stu-
dies [5,7,8]. The Resplex II assay is a multiplex PCR assay
coupled with bead array detection technology that is able
to detect multiple viruses including influenza A and influ-
enza B [7,8]. For each nasal wash specimen, total nucleic
acids were extracted using the DNA minikit (Qiagen, Inc,
Valencia, CA, USA) and 5 μl of extract were tested with
Resplex II on the LiquiChip 200 Workstation.
Specimens identified as Influenza A positive by the
Resplex II assay underwent additional singleplex real-time
PCR assays for H1, H3, or pandemic H1N1-2009 as pre-
viously described [5,9]. To determine the circulating
lineages of influenza, selected specimens were partially
sequenced by cDNA synthesis using the uni12primer
(AGCAAAAGCAGG) [10] with Transcriptor First Strand
cDNA synthesis Kit (Roche Diagnostics, Mannheim,
Germany). PCR amplification of the partial H1 gene and
H3 gene were carried out with primers described
previously [11]. The amplicons were then sequenced using
the primers and analysed with DNAstar, Lasergene version
7( M a d i s o n ,U S A ) .F o ri n f l u e nza B-positive specimens,
partial HA gene PCR amplification was obtained with in-
house designed primers (HA471F = 5’ACCTCAG-
GATCTTGCCCTAACG-3’ and HA1169R = 5’TGTGTAT
CCGTGCCAACCTGCAAT-3’) and sequenced with the
same primers as described for the sequencing of the influ-
enza A strains above.
Statistical analysis
To fulfil the main aim of the study, we analyzed the
overall clinical differences among pandemic influenza A
(H1N1-2009), influenza A (H3N2), and influenza B. Few
seasonal influenza A (H1N1) infections were detected
and these were therefore excluded from analyses, along
with influenza cases in which no subtype could be
determined due to insufficient sample quantity (44
cases, 1.5%), and patients with multiple co-infecting sub-
types (6 cases, 0.2%).
We performed two forms of statistical analysis. The first
conditions on influenza subtype and addresses the ques-
tions: given a patient is infected by this strain, how will his
illness express itself in terms of individual symptoms (or
signs), syndromes of pairs of symptoms, and overall symp-
tom load, relative to other aetiologies? Overall symptom
load was quantified by counting the symptoms or signs,
and differences in overall symptom load between strains
evaluated using linear models. Empirical proportions of
clinical presentation were used to assess patterns, for each
pair of strains, with logistic regression to evaluate differ-
ences in symptom expression. We evaluated the presence
of paired syndromes by assessing whether the joint distri-
butions of symptom pairs were more or less likely to
occur together using binomial tests, defining the excess
probability ratio to be the ratio of the proportion of cases
in which the pair occurred together relative to the product
of the marginal proportion of each symptom.
The second analysis conditions on the suite of symptoms
enumerated in this study and asks: given that the patient
has expressed this set of symptoms, what is the likely
aetiology? In this analysis, potential confounding was
addressed by multivariate analyses between pairs of strains,
with preliminary models containing all statistically signifi-
cant variables on univariate analysis across all subtypes,
before eliminating non-significant symptom variables
sequentially starting with the one with the highest p-value.
No interactions between variables were significant.
Statistical analyses were performed using R [12], with
a significance level of 0.05.
Results
A total of 2858 participants (98% of those eligible) were
recruited during the study period, with 2717 (95.1%)
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pants were mostly young adults (average age 21 years,
SD 3) and male (2853, 99.8%) due to the demographics
of the military setting. There were a total of 821 influ-
enza cases - of which 434 (52.9%) were pandemic
H1N1-2009, 58 (7.1%) seasonal H3N2, 269 (32.8%)
influenza B, and 10 (1.2%) seasonal H1N1. The influenza
vaccination status of the influenza cases is presented in
Table 1. The circulating strains during the study period
were the A/California/7/2009(H1N1)-like virus, A/Perth/
16/2009-(H3N2)-like virus, and influenza B from the
Victoria-lineage, closely related to the B/Brisbane/60/
2008-like virus. Figure 1 shows the distribution of influ-
enza cases over the course of the study.
From the comparison among the three main influenza
strains (pandemic H1N1-2009, seasonal H3N2, and influ-
enza B), pandemic H1N1-2009 cases had significantly
fewer symptoms or signs (mean 7.2, 95%CI 6.9-7.4, differ-
ence 1.6, 95%CI 1.2-2.0, p < 0.001) than the other two sub-
types (mean 8.7, 95%CI 8.5-9.0). There were no statistical
differences between H3N2 and influenza B (p =0 . 5 8 ) .T h e
patterns of symptoms expressed also differed substantially
between strains as shown in Figure 2. Pandemic H1N1-
2009 cases were significantly less likely to have nasal con-
gestion, eye or ear symptoms, chest pain, headache, high
fever, or injected pharynx compared to H3N2; and less
likely to have productive cough, sore throat, nasal conges-
tion, rhinorrhoea, eye or ear symptoms, chills or rigors,
myalgia or arthralgia, headache, high fever, or injected
pharynx, but more likely to have dry cough compared to
influenza B. H3N2 cases were associated with more dry
cough and rash but less productive cough or sore throat
than influenza B.
After adjusting for potential confounders as shown by
the multivariate analysis in Table 2, cases with nasal con-
gestion, rash, eye symptoms, injected pharynx or fever
were more likely to be infected with H3N2 than pandemic
H1N1-2009. Those with sore throat, fever, injected phar-
y n xo rr h i n o r r h o e aw e r em o r el i k e l yt ob ei n f e c t e dw i t h
influenza B than H1N1-2009, while dry cough patients
were more likely to be infected with H1N1-2009 than
influenza B. Those with nasalc o n g e s t i o no rr a s hw e r e
more likely to be infected with H3N2 than influenza B but
those with productive cough were more likely to be
infected with influenza B than H3N2. None of the subjects
required hospitalisation.
Figure 3 shows that some symptoms were significantly
associated (or dissociated) with other symptoms. Some are
obvious, such as dry and productive coughs which were
dissociated, while fever ≥ 37.8°C and fever ≥ 38°C were
associated. For pandemic H1N1-2009, some less common
symptom pairs appeared together more than twice as
often as expected: chest pain was strongly associated with
conjunctivitis, dyspnoea, diarrhoea and ear ache, while
nausea or vomiting was strongly associated with diarrhoea
and photophobia, and conjunctivitis with ear ache. Few
patients presented with both diarrhoea and a dry cough.
Many of the more common symptoms also appeared as
complexes, with the appearance of one increasing the
chances of the simultaneous expression of others. For
influenza B, chest pain also more frequently occurred if
accompanied by dyspnoea, nausea or vomiting, diarrhoea,
or ear ache; diarrhoea was often coupled with nausea or
vomiting; dyspnoea with ear ache; photophobia with con-
junctivitis or abnormal findings on clinical examination of
the lungs; while abnormal clinical lung findings more
often expressed themselves jointly with a dry cough than
expected by chance. There were too few H3N2 cases to
identify significant syndromes.
Discussion
Determining the clinical characteristics between circulat-
ing influenza strains is important for epidemiological deci-
sion making such as control and surveillance strategies,
and for clinicians to understand the symptom complexes
for different strains for patient management. Our peri-
pandemic period data shows the diversity of clinical pre-
sentations among influenza strains - it is important to
note that our results may only apply to the specific strains
that we studied, and may not apply to other strains in gen-
eral. Pandemic H1N1-2009 cases presented with fewer
symptoms overall compared to seasonal H3N2 or influ-
enza B cases, in spite of the propensity for pandemic
H1N1-2009 to affect older children and young adults [4].
This shows that although the extent of spread of the 2009
pandemic was substantial in this population, the clinical
severity may have been lower than even seasonal influenza
strains, resulting in a lower overall impact compared to
previous pandemics. In addition, as influenza spreads
quickly in closed environments such as the military,
schools, or boarding facilities [13], knowing the clinical
characteristics of existing influenza strains might help
raise the suspicion of novel influenza strains if marked
changes in clinical characteristics are noted, and to identify
novel strains for rapid initiation of control measures.
Our study showed that pandemic H1N1 cases were
less likely to present with high temperature, sore throat,
rhinorrhoea and injected pharynx compared to influenza
Table 1 Influenza vaccination status of influenza cases
Influenza cases Type of influenza vaccine received
Nil Pandemic vaccine Seasonal vaccine Both
H1N1pdm 345 33 46 10
H3N2 40 7 6 5
H1N1 10 0 0 0
B 41 212 2 14
Yap et al. BMC Infectious Diseases 2012, 12:12
http://www.biomedcentral.com/1471-2334/12/12
Page 3 of 7B cases; and less likely to present with high fever, rash,
nasal congestion, eye symptoms and injected pharynx
compared to H3N2 cases. A tropical study also found
that pandemic H1N1-2009 presented with fewer symp-
toms than seasonal influenza; including less fever, rhi-
norrhoea and dyspnoea but more cough [2]. However,
yet another found no differences in presentation
between pandemic H1N1 and other influenza subtypes
[14]. However, the latter two studies did not distinguish
between various seasonal influenza subtypes. A study
comparing adults with pandemic H1N1-2009 to those
with H3N2 found no statistically significantd i f f e r e n c e s
for a smaller set of 12 symptoms [15]. In our study, sub-
jects with nasal congestion or rash were more likely to
be infected with H3N2 than influenza B but those with
p r o d u c t i v ec o u g hw e r em o r el i k e l yt ob ei n f e c t e dw i t h
influenza B. Another study from France showed that
temperature of > 38.2°C, stiffness or myalgia, rhinor-
rhoea, and cough were predictive of H3N2 infection,
showing that differences exist for different strains in dif-
ferent settings [16].
Although reasons for different symptoms and syn-
dromes caused by influenza subtypes are not immediately
apparent, this may be related to host or viral factors which
have yet to be elucidated. This should form the basis for
further research into the pathogenic properties of influ-
enza subtypes and strains; and the possible linkages to
pre-existing immunity or cross-immunity from other
strains.
The differences in the clinical symptoms from the
influenza strains shown in this study also display the dif-
ficulty in using solitary descriptions of influenza (such as
traditional ILI definitions) with predictable accuracy for
clinical diagnosis and case management. The predictive
accuracy for influenza in any setting will depend on the
circulating influenza strains and other respiratory patho-
gens circulating locally. It is therefore important to com-
bine clinical syndromic surveillance with effective
laboratory testing. In the context of clinical management,
more sophisticated rapid tests may be required to identify
influenza cases with high sensitivity and specificity for
clinical management and public health measures to be
taken.
Our study’s strengths are its large sample size, high fol-
low-up rate, and high diagnostic ascertainment of influ-
enza subtypes. Limitations include selection bias towards
febrile symptomatic cases - although influenza may pre-
sent as milder infections, these are difficult to identify
through surveillance and we are concerned with more
severe clinical presentations resulting in absenteeism.
Figure 1 Distribution of influenza cases during study period. The top panel presents the weekly number of febrile respiratory infections per
1000 population. The bottom panel presents the proportion positive for each influenza subtype.
Yap et al. BMC Infectious Diseases 2012, 12:12
http://www.biomedcentral.com/1471-2334/12/12
Page 4 of 7Figure 2 Univariate comparison of clinical signs or symptoms between influenza subtypes. Symptoms or signs are ranked by average
frequency over the study period. Empirical frequencies of presentation of each symptom or sign are presented in the right column as bars, with
95% confidence intervals represented by whiskers. Symptoms or signs that have statistically discernible differences in frequencies for pairs of
strains at the 5% level are indicated in the significance matrix (SM) column. For instance, for a fever of 37.8 or above, pandemic H1N1 is
significantly different from the other two strains, indicated by orange and blue cells in the SM in the row for H1N1-2009, and the grey cell in the
rows for H3N2 and influenza B, but the latter have no statistically discernible difference, indicated by the white cells in their rows. With 63 tests,
the conservative expected number of false discoveries is 3, assuming no differences at all between strains.
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Influenza H1N1pdm vs H3N2*
Parameters Adjusted odds ratio (95% Confidence interval) pvalue
Blocked nose 0.33 (0.16, 0.72) 0.005
Rash 0.10 (0.02, 0.37) < 0.001
Eye symptoms 0.47 (0.24, 0.93) 0.03
Injected pharynx 0.45 (0.21, 0.97) 0.04
Fever (≥37.8°C) 0.33 (0.11, 0.99) 0.05
Influenza H1N1pdm vs B*
Parameters Adjusted odds ratio (95% Confidence interval) p value
Sore throat 0.44 (0.24, 0.80) 0.007
Fever (≥37.8°C) 0.51 (0.29, 0.92) 0.024
Injected pharynx 0.45 (0.29, 0.72) < 0.001
Age (per year) 1.25 (1.08, 1.46) 0.003
Dry cough 2.10 (1.25, 3.54) 0.005
Running nose 0.54 (0.34, 0.86) 0.009
Influenza H3N2 vs B*
Parameters Adjusted odds ratio (95% Confidence interval) p value
Blocked nose 3.00 (1.24, 7.19) 0.01
Rash 6.88 (1.50, 31.60) 0.01
Age (per year) 1.28 (1.09, 1.51) 0.002
Cough with sputum 0.24 (1.11, 0.51) < 0.001
*Age, dry cough, wet cough, sore throat, running nose, blocked nose, sore eyes or eye pain, chills/rigors, myalgia/arthralgia, ear symptoms, rash, chest pain,
headache, Fever ≥ 37.8°C, Fever ≥ 38.0°C, and injected pharynx were included in the analysis before non-significant terms were sequentially removed. With 48
tests, the conservative expected number of false discoveries is 2.4.
Figure 3 Symptom or sign complexes for A) H1N1-2009, B) Influenza B. Symptoms or signs are ranked by average frequency over the
study period over all strains. The expected proportion of symptom pairs assuming symptoms develop independently is the product of the two
marginal distributions. The discrepancy between this and the observed proportion of symptom pairs is assessed via a binomial test, with
differences that are significant at the 5% level represented by coloured cells, with the thickness of the cell wall indicating the p-value (thin
means 1% <p < 5%; medium, 0.1% <p < 1%; and thick, p < 0.1%). Colours encode the excess probability ratio, a measure of effect size, with
blue indicating a lower proportion and red a higher proportion observed than expected, and shade indicating the ratio of the empirical
proportion that the pair of symptoms appear together relative to what would be expected if their occurrence were independent. With 420 tests,
the conservative expected number of false discoveries is 21, assuming all symptoms or signs occur independently”.
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and results may not be generalizable to the overall popu-
lation, necessitating further studies to explore differences
in presentation among various age groups and gender.
Finally, the actual clinical impact of differentiating
between various influenza subtypes may be limited and
would depend on factors such as their current anti-viral
resistance profiles. However, this is not examined in this
study, and strains displaying anti-viral resistance may
have different clinical presentations.
Conclusion
Different influenza strains have different clinical presen-
tations in the young adult population, and pandemic
H1N1 influenza cases had fewer and milder clinical
symptoms than seasonal influenza H3N2 and B.
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